ImmunoCellular Therapeutics’ ICT-107 featured on CNN’s Sanjay Gupta MD
<0> For ImmunoCellular Therapeutics, Ltd.CEOcast, Inc.James Young, 212-732-4300Investor Relations </0>
ImmunoCellular Therapeutics (NYSE MKT: IMUC) a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it was featured on CNN’s Sanjay Gupta MD last weekend. The show profiled IMUC’s dendritic cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb clinical trial treating newly diagnosed patients with glioblastoma multiforme, an aggressive, terminal form of brain cancer.
Dr. Sanjay Gupta is the multiple Emmy®-award winning chief medical correspondent for CNN. Gupta, a practicing neurosurgeon, plays an integral role in CNN’s reporting on health and medical news for Starting Point with Soledad O'Brien, Anderson Cooper 360°, CNN documentaries, and anchors the weekend medical affairs program Sanjay Gupta MD. Gupta also contributes to CNN.com and CNNHealth.com.
ImmunoCellular’s Phase IIb trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107. The study is enrolling patients at medical institutions in collaboration with leading experts and opinion leaders in neuro-oncology.
A transcript of the CNN show can be found at:
ImmunoCellular Therapeutics () is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase IIb trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit .